Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oteseconazole in Recurrent Vulvovaginal Candidiasis
NCT03840616Phase 3Completed
- Sponsor
- Mycovia Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in vulvovaginal candidiasis (VVC) comparing Oteseconazole Arm with Fluconazole/Placebo Arm (2 arms). Primary endpoint: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase at 48 weeks. Started Mar 2019; status: completed.
02
Drugs
oteseconazole
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on NCT03840616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840616.